Biomarker discovery and identification from non-small cell lung cancer sera

Du, Jianjun; Sai, Yang; Lin, Xiuli; Shang, W.; Zhang, Wei; Huo, Shufen; Bu, Lina; Zhou, Bin; Nan, Yandong; Zheng, Huadong; Liu, Yanfeng

doi:10.2741/e214

Cited by 4 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, magnetic beads with large separation capacity have replaced ProteinChip for sample preparation and enrichment. Because magnetic beads are high-throughput, simple and quick to operate, beads based-ClinProt technology has been widely used in the researches of serum peptidome in solid tumors [ 20 - 24 ]. Previously, our group established a Quick classifier (QC) diagnostic model by ClinProt system, with a high sensitivity and specificity to discriminate adult AML patients from HCs.…”

Section: Introductionmentioning

confidence: 99%

Serum peptidome based biomarkers searching for monitoring minimal residual disease in adult acute lymphocytic leukemia

Bai

Huang

et al. 2014

Proteome Sci

View full text Add to dashboard Cite

BackgroundThe persistence of minimal residual disease (MRD) during therapy is the strongest adverse prognostic factor in acute lymphocytic leukemia (ALL). This study was to identify serum candidate peptides for monitoring MRD in adult ALL.ResultsA total of 33 peptides in the molecular weight range of 1000-10000 Da were detected using ClinProt system and statistically different between adult patients with ALL and healthy controls. Quick classifier (QC) algorithm was used to obtain a diagnostic model consisting of five peptides that could discriminate patients with ALL from controls with a high sensitivity (100%) and specificity (96.67%). The peptides in the QC model were identified as fibrinogen alpha chain (FGA), glutathione S-transferase P1 (GSTP1), isoform 1 of fibrinogen alpha chain precursor, platelet factor 4 (PF4) by high pressure/performance liquid chromatography mass spectrometry/mass spectrometry. Relative intensities of the five peptides were compared among ALL different groups for the potential importance of MRD evaluation in ALL. The peptides with increased relative intensities in newly diagnosed (ND) ALL patients were found to be decreased in their relative intensities after complete remission (CR) of adult ALL. When ALL patients were refractory & relapsed (RR), relative intensities of the peptides were elevated again. Peptides with decreased relative intensities in ND and RR ALL patients were found to be increased in their relative intensities when ALL patients achieved CR. The findings were validated by ELISA and western blot. Further linear regression analyses were performed to eliminate the influence of platelet and white blood cell counts on serum protein contents and indicated that there were no correlations between the contents of all four proteins (PF4, connective tissue active peptide III, FGA and GSTP1) and white blood cell or platelet counts in ALL different groups and healthy control.ConclusionsWe speculate the five peptides, FGA, isoform 1 of fibrinogen alpha chain precursor, GSTP1, PF4 and connective tissue active peptide III would be potential biomarkers for forecasting relapse, monitoring MRD and evaluating therapeutic response in adult ALL.Electronic supplementary materialThe online version of this article (doi:10.1186/s12953-014-0049-y) contains supplementary material, which is available to authorized users.

show abstract

Section: Introductionmentioning

confidence: 99%

Serum peptidome based biomarkers searching for monitoring minimal residual disease in adult acute lymphocytic leukemia

Bai

Huang

et al. 2014

Proteome Sci

View full text Add to dashboard Cite

show abstract

Mass spectrometry‐based proteomics: The road to lung cancer biomarker discovery

Indovina

Marcelli

Pentimalli³

et al. 2012

Mass Spectrometry Reviews

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer death in men and women in Western nations, and is among the deadliest cancers with a 5-year survival rate of 15%. The high mortality caused by lung cancer is attributable to a late-stage diagnosis and the lack of effective treatments. So, it is crucial to identify new biomarkers that could function not only to detect lung cancer at an early stage but also to shed light on the molecular mechanisms that underlie cancer development and serve as the basis for the development of novel therapeutic strategies. Considering that DNA-based biomarkers for lung cancer showed inadequate sensitivity, specificity, and reproducibility, proteomics could represent a better tool for the identification of useful biomarkers and therapeutic targets for this cancer type. Among the proteomics technologies, the most powerful tool is mass spectrometry. In this review, we describe studies that use mass spectrometry-based proteomics technologies to analyze tumor proteins and peptides, which might represent new diagnostic, prognostic, and predictive markers for lung cancer. We focus in particular on those findings that hold promise to impact significantly on the clinical management of this disease.

show abstract